08:26 AM EDT, 09/27/2024 (MT Newswires) -- MIRA Pharmaceuticals ( MIRA ) said Friday that preclinical data showed its oral ketamine analog Ketamir-2 achieved a "complete reversal of neuropathic pain in preclinical models."

In preclinical studies, Ketamir-2 showed "superior efficacy" compared with ketamine, the company said, adding that it is on track to submit an investigational new drug application to the US Food and Drug Administration by December.

MIRA Pharmaceuticals ( MIRA ) said it plans to show an efficacy signal in humans in 2025.

Shares of the company were up 2.8% in recent premarket activity.

Price: 1.1000, Change: +0.03, Percent Change: +2.80